Probabilistic Markov models in economic evaluation of health technologies: A practical guide;Los modelos de Markov probabilísticos en la evaluación económica de tecnologías sanitarias: Una guía práctica

Gaceta Sanitaria

Volumn 24, Issue 3, 2010, Pages 209-214

  Mar, Javier ^a   Antoñanzas, Fernando ^b   Pradas, Roberto ^b   Arrospide, Arantzazu ^a  

^a Hospital Alto Deba   (Spain)

^b UNIVERSITY OF LA RIOJA   (Spain)

Author keywords

Cost effectiveness study; Decision analysis; Markov models; Probabilistic sensitivity analysis

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; MEDICAL TECHNOLOGY; PROBABILITY; STATISTICAL MODEL;

BIOMEDICAL TECHNOLOGY; COST-BENEFIT ANALYSIS; HUMANS; MARKOV CHAINS; MODELS, STATISTICAL;

EID: 77954865889     PISSN: 02139111     EISSN: 15781283     Source Type: Journal    
DOI: 10.1016/j.gaceta.2010.02.006     Document Type: Article

References (23)

1. Drummond M.F., O'Brien B., Stoddart G.L., et al. Methods for the economic evaluation of health care programmes 2003, Oxford University Press, Oxford.
2. Mehrez A., Gafni A. Quality-adjusted life years, utility theory, and healthy years equivalent. Med Decis Making 1989, 9:142-149.
3. Roman R., Comas M., Hoffmeister L., et al. Determining the lifetime density function using a continuous approach. J Epidemiol Community Health 2007, 61:923-925.
4. Beck J.R., Kassirer J.P., Pauker S.G. A convenient approximation of life expectancy (the DEALE). I. Validation of the model. Am J Med 1982, 73:883-888.
5. Instituto Nacional de Estadística. Anuario estadístico de España 2009. (Acceso en octubre de 2009.) Disponible en: http://www.ine.es/prodyser/pubweb/anuario09/anu09_02demog.pdf.
6. Sonnenberg F.A., Beck R. Markov models in medical decision making: a practical guide. Med Decis Making 1993, 13:322-338.
7. Stahl J.E. Modelling methods for pharmacoeconomics and health technology assessment. An overview and guide. Pharmacoeconomics 2008, 26:131-148.
8. Excel Manual. Seattle: Microsoft; 2005.
9. TreeAge DATA™ Manual (versión profesional). Williamstown: TreeAge Software Inc.; 2004.
10. Briggs A.H., Goeree R., Blackhouse G., et al. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002, 22:290-308.
11. Mar J., Gutiérrez-Moreno S., Chilcott J. Análisis coste-efectividad de tipo probabilístico del tratamiento de la apnea del sueño. Gac Sanit 2006, 20:47-53.
12. Briggs A., Sculpher M., Claxton K. Decision modelling for health economic evaluation 2006, Oxford University Press, Oxford.
13. National Institute for Clinical Excellence. Guide to the methods of technology appraisal. NICE. 2004. London. (Acceso en septiembre de 2009.) Disponible en: http://www.nice.org.uk/niceMedia/pdf/TAP_Methods.pdf.
14. Hutter F., Antoñanzas F. Economic evaluations in the EURONHEED: a comparative analysis. Pharmacoeconomics 2009, 27:561-570.
15. Beck J.R., Pauker S.G. The Markov process in medical prognosis. Med Decis Making 1983, 3:419-458.
16. O'Brien B.J., Drummond M.F., Labelle R.J., et al. In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care 1994, 32:150-163.
17. Mar J., Begiristain J.M., Arrazola A. Cost-effectiveness analysis of thrombolytic treatment for stroke. Cerebrovasc Dis 2005, 20:193-200.
18. San Miguel R., Mar J., Cabasés J., et al. Cost-effectiveness analysis of therapeutic strategies for patients with chronic hepatitis C previously non-responders to interferon. Aliment Pharmacol Ther 2003, 17:765-773.
19. Mar J., Fernández-Artalejo F. Which is more important for the efficiency of hypertension treatment? The hypertension stage, the type of drug or the therapeutic compliance?. J Hypertens 2001, 19:149-155.
20. Stinnett A.A., Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998, 18(2 Suppl):S68-S80.
21. Claxton K., Neumann P.J., Araki S., et al. Bayesian value-of-information analysis: an application to a policy model of Alzheimer's disease. Int J Technol Asses Health Care 2001, 17:38-55.
22. Sacristán J.A., Oliva J., del Llano J., et al. ¿Qué es una tecnología sanitaria eficiente en España?. Gac Sanit 2002, 4:334-343.
23. Ortún V. 30.000 euros por AVAC. Economía y Salud 2004, 17:1-2.